The offer represents a 26% premium over the company's 60-day volume-weighted average price calculated through June 15. The acquisition marks a significant shift for the firm, which has struggled with market headwinds throughout 2026; its share price had dipped roughly 10% since January, closing at $16.37 prior to the trading halt. By folding the company into Chemical Computing Group, Altaris intends to consolidate its footprint in the specialized molecular design software market. The transaction is slated to finalize in the fourth quarter of 2026.
Altaris to Acquire Simulations Plus for $375 Million
Shareholders of Simulations Plus are set to receive $18.50 per share in an all-cash buyout by affiliates of Altaris, a deal valuing the drug development software firm at approximately $375 million. The acquisition, confirmed Tuesday, aims to merge the company into Altaris’ existing portfolio brand, Chemical Computing Group.
Comments (0)
No comments yet. Be the first!